Acacia Pharma has retained commercial rights to its product candidates in all territories and plans to commercialise them directly in the US and establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US.

The Group will also assess other hospital opportunities to utilise its future US sales and marketing infrastructure, including in-licensing or acquiring complementary product candidates.

To discuss opportunities, please contact